| 74.82 |  -0.71 / -0.94% |
Data as of 4:04pm ET | Day’s Change |
| 75.19 |  +0.3718 / +0.50% |
Volume: 1,000.00 |
| Favorable Verdict for Mylan - Analyst Blog 6:46pm / Zacks.com | Wider-Than-Expected Loss at Anacor - Analyst Blog May 13 / Zacks.com |
| Actavis: The latest Fortune 500 company to "leave" the U.S. for tax reasons May 21 / Fortune | Actavis: What it's like to join the Fortune 500 May 10 / Fortune |
| Previous close | 75.53 |
| Today’s open | 75.82 |
| Day’s range | 74.51 - 77.01 |
| Volume | 871,930 |
| Average volume (3 months) | 1,412,414 |
| Market cap | $22.9B |
| Dividend yield | -- |
| Earnings growth (last year) | -173.08% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +12.00% |
| Revenue growth (last year) | +43.97% |
| P/E ratio | 23.9 |
| Price/Sales | 5.15 |
| Price/Book | 6.17 |
| Today’s change | Today’s % change | |
|---|---|---|
| ALXNAlexion Pharmaceutic... | -2.10 | -2.05% |
| SHPGShire PLC | +0.10 | +0.10% |
| VRTXVertex Pharmaceutica... | -1.04 | -1.31% |
| ACTActavis Inc | -0.16 | -0.12% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $3.5B |
| Annual profit (last year) | -$116.0M |
| Net profit margin | -3.27% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman & Chief Executive Officer J. Michael Pearson, MBA |
Chief Financial Officer, Director & Executive VP Howard Bradley Schiller |
Corporate headquarters Montréal, Québec |
.
